Suggested Reading

Session 1

Brown EE, Lee YZJ, Halushka MK, et al. Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis. https://pubmed.ncbi.nlm.nih.gov/28494620/

Castano A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. October 2017. https://pubmed.ncbi.nlm.nih.gov/29019612/

Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis. J Nucl Cardiol. November 2019. April 2020.
Part 1: https://www.ahajournals.org/doi/10.1161/HCI.0000000000000029
Part 2: https://www.ahajournals.org/doi/10.1161/HCI.0000000000000030

Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. June 2016. https://pubmed.ncbi.nlm.nih.gov/27143678/

Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. October 2015. https://pubmed.ncbi.nlm.nih.gov/26224076/

Hanna M, Ruberg FL, Maurer MS, et al. Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis. J Am Coll Cardiol. June 2020. https://pubmed.ncbi.nlm.nih.gov/32498813/

Huda A, Castaño A, Niyogi A, Schumacher J, et al. A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy. Nat Commun. May 2021. https://pubmed.ncbi.nlm.nih.gov/33976166/

Quarta CC, Gonzalez-Lopez E, Gilbertson JA, et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J. June 2017. https://pubmed.ncbi.nlm.nih.gov/28605421/

Sperry BW, Reyes BA, Ikram A, et al. Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J Am Coll Cardiol. October 2018. https://pubmed.ncbi.nlm.nih.gov/30336828/

Westermark P, Westermark GT, Suhr OB, et al. Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis. Ups J Med Sci. August 2014. https://pubmed.ncbi.nlm.nih.gov/24620715/

Witteles RM, Liedtke M. Avoiding catastrophe: understanding free light chain testing in the evaluation of ATTR amyloidosis. https://pubmed.ncbi.nlm.nih.gov/33736459/

Session 2

The American College of Medical Genetics and Genomics recommendations for reporting of incidental findings in clinical exome and genome sequencing. https://www.ncbi.nlm.nih.gov/clinvar/docs/acmg/

Arvanitis M, Koch CM, Chan GG, et al. Identification of transthyretin cardiac amyloidosis using serum retinol-binding protein 4 and a clinical prediction model. JAMA Cardiol. March 2017. https://pubmed.ncbi.nlm.nih.gov/28196196/

Conceição I, Damy T, Romero M, et al. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid. March 2019. https://pubmed.ncbi.nlm.nih.gov/30793974/

Dang D, Fournier P, Cariou E, et al. Gateway and journey of patients with cardiac amyloidosis. ESC Heart Fail. October 2020. https://pubmed.ncbi.nlm.nih.gov/23474361/

Davis MK, Fine NM, Small GR, et al. Establishing a cardiac amyloidosis clinic: a practical primer for cardiologists. Can J Cardiol. April 2021. https://pubmed.ncbi.nlm.nih.gov/33485855/

Donnellan E, Elshazly MB, Vakamudi S, et al. No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis. JACC Clin Electrophysiol. December 2019. https://pubmed.ncbi.nlm.nih.gov/31857048/

Donnellan E, Wazni OM, Saliba WI, et al. Cardiac devices in patients with transthyretin amyloidosis: impact on functional class, left ventricular function, mitral regurgitation, and mortality. J Cardiovasc Electrophysiol. November 2019. https://pubmed.ncbi.nlm.nih.gov/31515942/

Feng D, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. November 2007. https://pubmed.ncbi.nlm.nih.gov/17984380/

Garcia-Pavia P, Bengel F, Brito D, et al. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. Eur Heart J. June 2021. https://pubmed.ncbi.nlm.nih.gov/33915002/

Griffin JM, Rosenblum H, Maurer MS. Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ Res. May 2021. https://pubmed.ncbi.nlm.nih.gov/33983835/

Hamon D, Algalarrondo V, Gandjbakhch E, et al.. Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis. Int J Cardiol. November 2016. https://pubmed.ncbi.nlm.nih.gov/27513652/

Judge DP, Kristen AV, Grogan M, et al. Phase 3 multicenter study of revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. June 2020. https://pubmed.ncbi.nlm.nih.gov/32062791/

Kazi DS, Bellows BK, Baron SJ, et al. Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy. Circulation. April 2020. https://pubmed.ncbi.nlm.nih.gov/32078382/

Kittleson MM, Cole RM, Patel J, et al. Mechanical circulatory support for cardiac amyloidosis. Clin Transplant. October 2019. https://pubmed.ncbi.nlm.nih.gov/31309629/

Kristen AV, Kreusser MM, Blum P, et al. Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. J Heart Lung Transplant. May 2018. https://pubmed.ncbi.nlm.nih.gov/29217108/

Lousada, I, Comenzo, RL, Landau, H, et al. Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium. Adv Ther. October 2015. https://pubmed.ncbi.nlm.nih.gov/26498944/

Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. September 2018. https://pubmed.ncbi.nlm.nih.gov/30145929/

Nativi-Nicolau J, Sarswat N, Fajardo J, et al. Best practices in specialized amyloidosis centers in the united states: a survey of cardiologists, nurses, patients, and patient advocates. Clinical Medicine Insights: Cardiology. January 2021. https://pubmed.ncbi.nlm.nih.gov/34104028/

Schonhoft JD, Monteiro C, Plate L, et al. Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients. Sci Transl Med. September 2017. https://pubmed.ncbi.nlm.nih.gov/28904227/

Shah SJ, Cogswell R, Ryan JJ, et al. How to develop and implement a specialized heart failure with preserved ejection fraction clinical program. Curr Cardiol Rep. December 2016. https://pubmed.ncbi.nlm.nih.gov/27796858/

Swiecicki PL, Edwards BS, Kushwaha SS, et al. Left ventricular device implantation for advanced cardiac amyloidosis.J Heart Lung Transplant. May 2013. https://pubmed.ncbi.nlm.nih.gov/23474361/